SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ProMetic Life Sciences
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: axial11/17/2016 11:33:43 AM
   of 250
 
Analysis — Panmure Gordon 17 Nov 2016

docdro.id
  • ProMetic continues to post positive and significant results from the multiple PBI-4050 clinical trials. The open IPF (idiopathic pulmonary fibrosis) Phase 2 clinical trial has shown early evidence of efficacy alone and in combination with one of the commercially approved drug for IPF. This follows news of significant results with metabolic syndrome & Type 2 diabetes, and liver fibrosis in H2/16 so far.
  • The first 30 IPF patients treated with PBI-4050 or PBI-4050 and one of the commercial drugs for 12 weeks saw their FVC (forced vital capacity) improve by 10ml. In comparison, IPF patients treated with either pirfenidone or nintedanib in the ASCEND and two INPULSIS Phase 3 clinical trials saw their FVC decline by 25-30ml after 13 weeks of treatment whilst placebo patients declined by 75-100ml. While preliminary, these results are very promising. The distribution of the 30 patients in the trial was as follows: 27.5% PBI-4050 monotherapy, 35% PBI-4050 + pirfenidone, 37.5% PBI-4050 + nintedanib.
  • Furthermore, none of the patients treated with PBI-4050 experienced a decline of greater or equal to 10% in FVC or death during the 12 weeks treatment. In comparison, 7.5 % of patients in the ASCEND Phase 3 trial had a greater or equal to 10% decline in FVC or death after 13 weeks (5% on placebo and 2.5% on treatment).
  • IPF is a chronic, progressive, and fatal lung disease that is characterised by irreversible loss of lung function. Although periods of transient clinical stability may be observed, continued progression of the disease is inevitable.2 The prognosis is poor, with a 5-year survival rate that is similar to the rates for several cancers.
______________________________________

Hat tip: bepando

Jim
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News